Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.5.4.4 (adenosine deaminase)
 5,136 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Phosphatidylcholine secretion in type II pneumocytes can be stimulated by P1 (adenosine) and P2 (ATP) purinoceptor agonists. The effect of adenosine is mediated by the A2 subtype of the P1 receptor. The A1 subtype is inhibitory. We examined the influence of ATP and the A2 agonist 5'-(N-ethylcarboxyamido)adenosine (NECA) on phosphatidylcholine secretion in primary cultures of rat type II cells. The stimulatory effects of ATP and NECA were less than additive, suggesting a common mechanism of action. NECA and ATP both caused a rapid increase in cAMP, and the combination enhanced this even further. ATP promoted inositol trisphosphate (IP3) formation, whereas NECA did not. The effect of ATP on adenosine 3',5'-cyclic monophosphate (cAMP) but not on IP3 was abolished by a P1 antagonist, and such antagonists diminished its effect on secretion by as much as 75%. The potency orders of ATP analogues in increasing formation of cAMP and IP3 were different. The effects of the ATP analogues on phosphatidylcholine secretion were also inhibited by the P1 antagonists, with the greatest degree of inhibition being observed with the analogue that increased cAMP to the greatest extent. The effect of ATP on secretion was not diminished by either adenosine deaminase (previous data) or AMP deaminase showing that the effects of ATP were not mediated by its metabolism to the P1 agonists adenosine or AMP. These data show that ATP acts at both A2 and P2 receptors but that most of its effects on phosphatidylcholine secretion are mediated by the A2 receptor.
 ...
PMID:A2 and P2 purine receptor interactions and surfactant secretion in primary cultures of type II cells. 165 64

Phosphatidylcholine secretion in type II pneumocytes has been reported to be stimulated by P1 and P2 purinoceptor agonists. P1 receptors are divided into A1 and A2 subtypes with opposite effects on the levels of adenosine 3',5'-cyclic monophosphate (cAMP). Stimulated secretion in type II cells is mediated by the A2 receptor and accompanied by an increase in cAMP concentration. We now report evidence suggesting the existence of an A1 receptor-inhibiting secretion in type II cells from adult rats. The rate of phosphatidylcholine secretion was approximately doubled by 5'(N-ethylcarboxyamido) adenosine (NECA), terbutaline, and forskolin, all of which increase cAMP levels. Adenosine deaminase increased the stimulatory effect of these agonists to approximately three-fold but it had not effect on secretion stimulated by agonists which do not increase cAMP levels. The effect of adenosine deaminase on terbutaline-stimulated secretion was antagonized by selective adenosine A1 receptor agonists, N6-cyclopentyladenosine (CPA) and 1-deaza-2-chloro-N6-cyclopentyladenosine (DCCA). The maximum inhibitory effects of CPA and DCCA were achieved at 10(-9) M and 10(-11) M, respectively. At these concentrations CPA and DCCA had no effect on the rate of basal secretion or on terbutaline-stimulated secretion in the absence of adenosine deaminase. We suggest that adenosine deaminase stimulates phosphatidylcholine secretion by removing adenosine that occupies A1 receptors, thus reversing inhibition of cAMP-mediated secretion.
 ...
PMID:Adenosine A1 receptor-mediated inhibition of surfactant secretion in rat type II pneumocytes. 230 99